Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...